scholarly journals Clinical significance of pulmonary nodules detected by CT and Not CXR in patients treated for favorable histology Wilms tumor on national Wilms tumor studies-4 and -5: A report from the Children's Oncology Group

2012 ◽  
Vol 59 (4) ◽  
pp. 631-635 ◽  
Author(s):  
Paul E. Grundy ◽  
Daniel M. Green ◽  
Astrid C. Dirks ◽  
Andrea E. Berendt ◽  
Norman E. Breslow ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Wilms Tumor ◽  
Pulmonary Nodules ◽  
Oncology Group ◽  
Favorable Histology ◽  
Tumor Studies

scholarly journals Outcome of Wilms tumor patients with bone metastasis enrolled on National Wilms Tumor Studies 1-5: A report from the Children's Oncology Group

2018 ◽  
Vol 66 (1) ◽  
pp. e27430 ◽  
Author(s):  
Douglas S. M. Iaboni ◽  
Yueh-Yun Chi ◽  
Yeonil Kim ◽  
Jeffrey S. Dome ◽  
Conrad V. Fernandez
Keyword(s):  
Bone Metastasis ◽  
Wilms Tumor ◽  
Oncology Group ◽  
Tumor Patients ◽  
Tumor Studies

Treatment outcomes in patients less than 2 years of age with small, stage I, favorable-histology Wilms' tumors: a report from the National Wilms' Tumor Study.

1993 ◽  
Vol 11 (1) ◽  
pp. 91-95 ◽  
Author(s):  
D M Green ◽  
N E Breslow ◽  
J B Beckwith ◽  
J Takashima ◽  
P Kelalis ◽  
...  
Keyword(s):  
Wilms Tumor ◽  
Stage I ◽  
P Value ◽  
Relapse Free Survival ◽  
Free Survival ◽  
Treatment Regimens ◽  
Survival Percentage ◽  
Favorable Histology ◽  
Specimen Weight ◽  
Tumor Studies

PURPOSE Retrospective analyses were performed to determine the effect of tumor weight and therapy modifications on outcome in patients less than 2 years of age with stage I favorable-histology Wilms' tumors. PATIENTS AND METHODS The 4-year relapse-free and overall survival percentages for patients randomized to different treatment regimens in National Wilms' Tumor Studies (NWTS)-1, -2, and -3 were calculated and compared. RESULTS The 4-year relapse-free survival percentages of patients whose specimen weight was less than 550 g were found to be 89.1% on NWTS-1, 96.0% on NWTS-2, and 93.2% on NWTS-3. There was no evidence that the relapse-free survival of these patients had improved over time (P value for trend = .99). The 4-year relapse-free survival percentage for similar age and stage patients whose specimen weight was 550 g or greater was significantly poorer than that of patients with smaller tumors (P = .02). CONCLUSION Changes in the NWTS treatment regimens over a period of more than 20 years have not improved on the excellent prognosis of patients who are less than 2 years of age at diagnosis and who have a stage I, favorable-histology Wilms' tumor with specimen weight less than 550 g. These data could be used as the basis for a future trial in which a subgroup of such patients is treated with nephrectomy only.

scholarly journals Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression Analysis: A Report from the Renal Tumor Committee of the Children's Oncology Group

2009 ◽  
Vol 15 (5) ◽  
pp. 1770-1778 ◽  
Author(s):  
Chiang-Ching Huang ◽  
Samantha Gadd ◽  
Norman Breslow ◽  
Colleen Cutcliffe ◽  
Simone T. Sredni ◽  
...  
Keyword(s):  
Gene Expression ◽  
Expression Analysis ◽  
Gene Expression Analysis ◽  
Renal Tumor ◽  
Wilms Tumor ◽  
Oncology Group ◽  
Favorable Histology

Outcome and prognostic factors in stage III favorable histology Wilms tumor (FHWT): A report from the Children’s Oncology Group (COG) study AREN0532.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 10010-10010 ◽  
Author(s):  
Conrad Vincent Fernandez ◽  
Elizabeth Anne Mullen ◽  
Peter F. Ehrlich ◽  
John A. Kalapurakal ◽  
Geetika Khanna ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Wilms Tumor ◽  
Stage Iii ◽  
Oncology Group ◽  
Favorable Histology

Summary of Annual Meeting of Section on Pediatric Urology

PEDIATRICS ◽  
1990 ◽  
Vol 85 (5) ◽  
pp. 872-878
Author(s):  
Stephen A. Kramer
Keyword(s):  
Prognostic Factors ◽  
Annual Meeting ◽  
Metastatic Disease ◽  
Wilms Tumor ◽  
Pediatric Urology ◽  
Response To Treatment ◽  
Prognostic Indicators ◽  
Favorable Histology ◽  
Tumor Studies ◽  
The University

The Section on Urology of the American Academy of Pediatrics met for 2½ days in conjunction with the 58th Annual Meeting of the Academy in Chicago, IL, October 21 to October 23, 1989. The papers presented at this meeting that were thought to be of interest to the practicing pediatrician are summarized here according to topic. The recipient of this year's Pediatric Urology Medal is Jack Lapides. Dr Lapides is recognized for his numerous academic achievements and his excellence in teaching as Professor and Chairman of the Department of Urology at the University of Michigan. His introduction and popularization of intermittent self-catheterization has revolutionized the treatment of neurogenic bladder dysfunction and is clearly one of the most significant contributions to urology during the past few decades. GENITOURINARY TUMORS Those of us involved in the care of patients with Wilms tumor continue to search for prognostic indicators which will allow identification of patients at low risk or high risk for the development of metastatic disease. The accumulated data from National Wilms' Tumor Studies II and III showed that decreasing amounts of chemotherapy can be administered to patients with favorable prognostic factors, whereas patients with poor prognostic factors require more aggressive chemotherapy and radiation therapy. While favorable histology and the absence of nodal metastatic disease have clearly been shown to be associated with enhanced survival, Gearhart and coworkers have used nuclear morphometry to predict response to treatment in patients with Wilms tumor. In a retrospective analysis of 29 patients with Wilms tumor, morphometric nuclear analysis (using several shape descriptors) was very useful in identifying responders vs nonresponders to chemotherapy.

Treatment of stage IV favorable histology Wilms tumor with incomplete lung metastasis response after chemotherapy: A report from Children’s Oncology Group study AREN0533.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 10001-10001 ◽  
Author(s):  
David B. Dix ◽  
Eric J. Gratias ◽  
Nita Seibel ◽  
James Robert Anderson ◽  
Elizabeth Anne Mullen ◽  
...  
Keyword(s):  
Lung Metastasis ◽  
Wilms Tumor ◽  
Stage Iv ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Favorable Histology

scholarly journals Outcomes of Children With Favorable Histology Wilms Tumor and Peritoneal Implants Treated in National Wilms Tumor Studies-4 and -5

2010 ◽  
Vol 77 (2) ◽  
pp. 554-558 ◽  
Author(s):  
John A. Kalapurakal ◽  
Daniel M. Green ◽  
Gerald Haase ◽  
James R. Anderson ◽  
Jeffrey S. Dome ◽  
...  
Keyword(s):  
Wilms Tumor ◽  
Favorable Histology ◽  
Peritoneal Implants ◽  
Tumor Studies

scholarly journals Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children’s Oncology Group Study AREN0532

2018 ◽  
Vol 36 (3) ◽  
pp. 254-261 ◽  
Author(s):  
Conrad V. Fernandez ◽  
Elizabeth A. Mullen ◽  
Yueh-Yun Chi ◽  
Peter F. Ehrlich ◽  
Elizabeth J. Perlman ◽  
...  
Keyword(s):  
Overall Survival ◽  
Radiation Therapy ◽  
Lymph Node ◽  
Residual Disease ◽  
Wilms Tumor ◽  
Stage Iii ◽  
Lymph Node Status ◽  
Oncology Group ◽  
Favorable Histology ◽  
Node Status

Background The National Wilms Tumor Study (NWTS) approach to treating stage III favorable-histology Wilms tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy. Further risk stratification is required to improve outcomes and reduce late effects. We evaluated clinical and biologic variables for patients with stage III FHWT without combined loss of heterozygosity (LOH) at chromosomes 1p and 16q treated in the Children’s Oncology Group protocol AREN0532. Methods From October 2006 to August 2013, 588 prospectively treated, centrally reviewed patients with stage III FHWT were treated with Regimen DD4A and radiation therapy. Tumor LOH at 1p and 16q was determined by microsatellite analysis. Ineligible patients (n = 5) and those with combined LOH 1p/16q (n = 40) were excluded. Results A total of 535 patients with stage III disease were studied. Median follow-up was 5.2 years (range, 0.2 to 9.5). Four-year event-free survival (EFS) and overall survival estimates were 88% (95% CI, 85% to 91%) and 97% (95% CI, 95% to 99%), respectively. A total of 58 of 66 relapses occurred in the first 2 years, predominantly pulmonary (n = 36). Eighteen patients died, 14 secondary to disease. A better EFS was associated with negative lymph node status ( P < .01) and absence of LOH 1p or 16q ( P < .01), but not with gross residual disease or peritoneal implants. In contrast, the 4-year EFS was only 74% in patients with combined positive lymph node status and LOH 1p or 16q. A total of 123 patients (23%) had delayed nephrectomy. Submitted delayed nephrectomy histology showed anaplasia (n = 8; excluded from survival analysis); low risk/completely necrotic (n = 7; zero relapses), intermediate risk (n = 63; six relapses), and high-risk/blastemal type (n=7; five relapses). Conclusion Most patients with stage III FHWT had good EFS/overall survival with DD4A and radiation therapy. Combined lymph node and LOH status was highly predictive of EFS and should be considered as a potential prognostic marker for future trials.

Sign in / Sign up

Export Citation Format

Share Document